Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer
Author:
Funder
Projects of Health and Family Planning Commission of Sichuan Province, China
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference23 articles.
1. G. North East Japan gefitinib study, first-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy;Inoue;J. Clin. Oncol.,2009
2. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N. Engl. J. Med.,2009
3. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib;Omuro;Cancer,2005
4. Leptomeningeal carcinomatosis;Grossman;Cancer Treat. Rev.,1999
5. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors;Lee;J Thorac Oncol,2013
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer (BLOSSOM);Journal of Clinical Oncology;2024-08-10
2. Thérapies dans la méningite carcinomateuse du cancer du poumon, du sein et le mélanome : revue systématique de la littérature;Pratique Neurologique - FMC;2024-06
3. Double-dose osimertinib combined with intrathecal injection of pemetrexed improves the efficacy of EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis: case report and literature review;Frontiers in Oncology;2024-04-22
4. Clinical Characteristics and Prognostic Factors of Leptomeningeal Metastasis in Nonsmall Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutations;2024
5. Increasing discrepancy of MR imaging and CSF study in patients with leptomeningeal seeding from lung adenocarcinoma after targeted therapy using a tyrosine kinase inhibitor;Medicine;2023-10-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3